Germany Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Dec. 1, 2006 - 69 Pages

Table of Contents

Chapter 1 - Executive Summary

Germany Pharmaceuticals & Healthcare Industry SWOT

Germany Political SWOT

Germany Economic SWOT

Chapter 2 - Germany: Business Environment Ranking

Table: Western Europe Business Environment Rankings

Economics - Long Term risk

Politics - Long Term risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Germany: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Developments

Pricing & Reimbursement Issues

Retail Industry

Chapter 5 - Industry Developments

Healthcare Sector

Pharmaceutical Sector

Domestic Industry

Krankenkasse

Foreign Industry

R&D Sector

Generics Sector

Offshoring Sector

Biotech Sector

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: German Drug Market Expenditure Forecasts 2005-2010

Key Growth Factors - Industry

Table: German Health Expenditure Forecast Indicators 2004-2010

Key Growth Factors - Macroeconomic

Table: Germany - Macroeconomic Forecasts

Prescription Market Forecast

Table: Germany Prescription Drugs Market Forecast Indicators

OTC Market Forecast

Table: German OTC Market Forecast Indicators 2005-20

Generics and Branded Market Forecasts

Table: German Generics and Branded Market Forecast Indicators 2005-2010

Export/Import Forecasts

Table: German Pharmaceuticals Exports & Imports Forecasts 2005-2010

Germany Pharmaceuticals & Healthcare Report Q3 2006

Key Risks to BMI’s Forecast Scenario

Chapter 7 - Country Snapshot: Germany Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Table: Wages per year

Chapter 8 - Competitive Landscape

Overview .

Chapter 9 - Company Profiles

GlaxoSmithKline

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Bayer

Boehringer Ingelheim

Schering AG

Chapter 10 - BMI Forecast Modelling

How we generate our industry forecasts

Technical Process

Pharmaceutical Industry

Chapter 11 - Sources

Abstract

Cost-containment, government intervention and the promotion of generics are the key drivers in the German pharmaceutical sector. Nevertheless, the prescription drugs market is expected to continue growing in the next few years, reaching a valuation of just over US$65bn by 2010.

Flying in the face of medicines legislation designed to control spending, German pharmaceuticals turnover for the period January to May 2006 rose by 7% to EUR10.7bn (US$13.2bn), driven by robust demand from the hospital sector. This sector grew strongly as it tends to include medicines that have no generic competition. Sales of atypical antipsychotics, beta-interferons, Parkinson's disease treatments and immunosupressants all grew by 10% as new drugs entered the market and generic competition remained negligible. Because of an ageing population, growth in the hospital medicines sector is historically high and occurred despite disruption caused by healthcare worker strikes and the introduction of savings legislation. The new medicines law will probably take longer to have any measurable effect on this sector compared to others, such as the general practitioner market. However, this lag-time will provide generics manufacturers with a major source of growth in the coming years.

BMI's adjusted Business Environment Rankings for Western Europe reveal that Germany has maintained its position as the premier country for pharmaceuticals, ahead of the Switzerland, UK, France and Italy. The country scores highly for political risk (Germany's recently elected coalition has deemed healthcare reform as a fast-track issue) and market size. Germany posted relatively low scores for market growth and domestic sector threat (the country is home to several of the world's largest multinationals, like Bayer, Merck KGaA, Boehringer Ingelheim and Schering AG.

Talks to decide the future of German healthcare finished recently in a compromise that will allow funding to be broadly restructured. However, measures to control medicines' prices have alarmed pharmacists and the pharmaceutical industry. The reforms - championed by the Christian Democrats and Social Democrats - proposed a system of maximum prices for medicines and raising the health fund contribution rates by 0.5%. Annual savings of EUR500mn (US$643mn) should be realised when the legislation is implemented.

There is still a lack of effective management in medicines prescribing in Germany, with patients frequently prescribed unnecessary drugs. Substitution of branded products with generics could still take place on a much larger scale, according to the Gmunder Krankenkassen. Savings of 20% - or EUR2.3bn (US$3bn) - could be made if the full range of substitutions occurred. Additionally, the organisation revealed that the Krankenkasse spend half of their medicines budget on the over-65s.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.